Comparative Pharmacology
Head-to-head clinical analysis: ROZLYTREK versus TASIGNA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ROZLYTREK versus TASIGNA.
ROZLYTREK vs TASIGNA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Entrectinib is a potent inhibitor of tropomyosin receptor tyrosine kinases (TRK) A, B, and C, and also inhibits ROS1 and ALK. It blocks downstream signaling pathways including MAPK, PI3K/AKT, and PLCγ, leading to apoptosis and reduced tumor growth in cancers with NTRK or ROS1 fusions.
Nilotinib is a tyrosine kinase inhibitor that binds to and inhibits the activity of BCR-ABL, the constitutively activated fusion protein responsible for chronic myeloid leukemia (CML). It also inhibits other kinases including KIT, PDGFR, and DDR1.
200 mg orally once daily with or without food.
400 mg orally twice daily approximately every 12 hours. Administer on an empty stomach (no food for at least 2 hours before and 1 hour after dose). Swallow whole with water; do not crush or chew.
None Documented
None Documented
Terminal half-life approximately 24 hours; supports once-daily dosing, steady-state reached in ~5 days.
Terminal elimination half-life is approximately 90-120 hours, supporting once-daily dosing.
Primarily hepatic metabolism via CYP3A4; 63% of dose recovered in feces (mostly as metabolites), 18% in urine (9% unchanged).
Primarily fecal (approximately 66-93% of the dose) as unchanged drug and metabolites; renal excretion is minimal (<5% of the dose).
Category C
Category C
Tyrosine Kinase Inhibitor
Tyrosine Kinase Inhibitor